Acadia Pharmaceuticals' CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, highlighting the role of AI in its strategy.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it expands into the rare disease space, with AI playing a major role in its marketing strategy.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, its expansion into rare disease and how it's using AI throughout commercialization and marketing.
Adams shares insights on the benefits and challenges of marketing as a smaller biotech and how her marketing background is helping steer the company into 2026.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.
- Rebranding and expansion into rare disease space
- Role of AI in marketing strategy
- Challenges and benefits of marketing as a smaller biotech
More News
- WAFCON Qualifier: Oshoala, Omewa, seven others arrive camp
- Nasdaq Futures Climb 100 Points as Big Earnings Approach - Schaeffer's Investment Research
- ICC dismisses Israel's appeal against arrest warrants for Netanyahu, Gallant
- West London level crossing revamp to bring journey changes over October half-term
- Should public service managers get bonuses in a time of cuts?
- Trump implies US will purchase Argentinian beef to lower prices for Americans
- Auburn volleyball drop third straight, swept in tight match at Tennessee - The Auburn Plainsman
- How the U.S. Failure in Iraq Haunts Trump’s Gaza Plan
- AWS DNS Failure Shuts Down Alexa, Fortnite, ChatGPT, PlayStation Network, and More
- Christian Animated Kids TV Show Climbs Amazon Prime Video Charts